以岭药业跌2.01%，成交额3.47亿元，主力资金净流出3907.66万元

Core Viewpoint - Yiling Pharmaceutical's stock price has shown a year-to-date increase of 24.19%, but has recently experienced a decline of 4.69% over the past five trading days, indicating volatility in its market performance [1]. Financial Performance - For the period from January to September 2025, Yiling Pharmaceutical reported a revenue of 5.868 billion yuan, representing a year-on-year decrease of 7.82%. However, the net profit attributable to shareholders increased by 80.33% to 1 billion yuan [2]. - The company has cumulatively distributed 4.455 billion yuan in dividends since its A-share listing, with 1.838 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Yiling Pharmaceutical was 152,700, a decrease of 10.22% from the previous period. The average number of circulating shares per shareholder increased by 11.38% to 9,013 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 25.704 million shares, an increase of 8.112 million shares compared to the previous period. Meanwhile, the Southern CSI 500 ETF reduced its holdings by 256,900 shares [3]. Market Activity - Yiling Pharmaceutical's stock experienced a trading volume of 347 million yuan with a turnover rate of 1.28% as of November 18. The total market capitalization stood at 32.595 billion yuan [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 64.0503 million yuan on January 6, accounting for 14.28% of total trading volume [1].